GautamPrasadMDPhD

PubMed

• 65 citations
  Sixteen facial expressions occur in similar contexts worldwide
  Alan S. Cowen, Dacher Keltner, Florian Schroff, Brendan Jou, Hartwig Adam
  Nature. 2021-01-14
• 4 citations
  Author Correction: The challenge of mapping the human connectome based on diffusion tractography.
  Klaus H. Maier-Hein, Peter F. Neher, Jean-Christophe Houde, Marc-Alexandre Côté, Eleftherios Garyfallidis
  Nature Communications. 2019-11-04
• Re: The Influence of Online Forums on Radiation Oncology Residency Program Selection.
  Laura Turner, Kimberli Cox, Gautam Prasad
  International Journal of Radiation Oncology, Biology, Physics. 2019-09-01

Journal Articles

• Suberoylanilide hydroxamic acid (SAHA) and Radiation for the Treatment of metastatic Neuroblastoma  
  Mueller S, Yang X, Sottero T, Prasad G , Polley, MY, Matthay K, Dubois S, Weiss, W, Haas-Kogan D, Cancer Lett., 1/1/2011
• Radiation induced gliomas  
  Prasad G, Haas-Kogan DA, Expert Rev Neurother, 1/1/2009
• Determination of desoxyepothilone B in nude mice plasma by liquid-liquid extraction and reversed -phase high-performance liquid chromatography  
  Wang Z, Wang H, Rhie JK, Covey JM, Liang P, Wang S, Wang C, Hu Y, Prasad G, Nan L, Hill DL, Zhang R, J Pharm Biomed Anal., 1/1/2006
• Radiosensitization by antisense-MDM2 mixed backbone oligonucleotides in in vitro and in vivo human cancer models  
  Zhang Z*, Wang H*, Prasad G*, Mao L, Yu D, Bonner JA, Agrawal S, and Zhang R, Clin Cancer Res., 1/1/2004
• Recent advances in experimental molecular therapeutics for malignant gliomas  
  Prasad G, Wang H, Hill D, Zhang R, Curr Med Chem Anti-Canc Agents, 1/1/2004
• Antisense oligonucleotides targeted to MDM2 oncogene as a novel approach to the treatment of glioblastoma multiforme  
  Prasad G, Wang H, Agrawal S, and Zhang R, Anticancer Res, 1/1/2002
• Antisense anticancer oligonucleotide therapeutics  
  Wang H, Prasad G, Buolamwini JK, and Zhang R, Curr Cancer Drug Targets, 1/1/2001
• Join now to see all

Abstracts/Posters

• Vorinostat and Radiation for the Treatment of Metastatic Neuroblastoma.
  Prasad G. Mueller S, Yang X, Sottero T,.Polley M, Matthay K, DuBois S, Weiss W, Haas-Kogan D, American Society for Radiation Oncology (ASTRO) Annual Meeting, San Diego, CA, 11/1/2010
• Rational incorporation of novel agents into multimodality treatment of glioma and neuroblastoma.
  Haas-Kogan D, Prasad G, Mueller S, Yang X, DuBois S, Sottero T, Polley M, James D, Berger M, Prados M, Aftab D, Matthay K, American Association for Cancer Research (AACR) Annual Meeting, Washington, DC, 4/1/2010
• Inhibition of PI3K/mTOR Pathways in Glioblastoma and Implications for Combination Therapy with Erlotinib, Temozolomide, and Radiation.
  Prasad G, Sottero T, Yang X, Mueller S, James D, Berger M, Aftab D, Prados M, Haas-Kogan D, American Society for Radiation Oncology (ASTRO) Annual Meeting, Chicago, IL, 11/1/2009
• Inhibition of PI3K/mTOR Pathways in Glioblastoma and Implications for Combination Therapy with Erlotinib, Temozolomide, and Radiation.
  Prasad G, Sottero T, Yang X, Mueller S, James D, Berger M, Aftab D, Prados M, Haas-Kogan D, Society of Neuro Oncology Annual Meeting, New Orleans, LA, 10/1/2009
• Combined modality therapy with radiation, temozolomide, and PI3-kinase inhibitors for the potential treatment of malignant gliomas.
  Prasad G, Mueller S, Yang X, James D, Berger M, Prados MD, Haas-Kogan D, Society of Neuro Oncology Annual Meeting, Lake Las Vegas, NV, 11/1/2008
• Outcomes following radiosurgery for the treatment of primary or metastatic intracranial sarcomas.
  Prasad G, McDermott MW, Sneed PK, ASTRO Annual Meeting, Boston, MA, 9/1/2008
• Inhibition of PI3K/mTOR Pathways in Glioblastoma and Implications for Combination Therapy with Erlotinib, Temozolomide, and Radiation.
  Prasad G, Sottero T, Yang X, Mueller S, James D, Berger M, Aftab D, Prados M, Haas-Kogan D, UCSF Multi-disciplinary Clinical/translational Science Research Symposium for Residents, San Francisco, CA, 6/1/2008
• Expression of vascular endothelial growth factor (VEGF) following radiation, etoposide or cisplatin treatment in small cell lung cancer.
  Prasad G, Raisch KP, Bonner JA, ASTRO Annual Meeting, Philadelphia, PA, 11/1/2006
• Dosimetric comparison of IMRT boost vs. CK boost for complex skull base tumors.
  Prasad G, Chuang C, Larson D, Nakamura J, Annual CyberKnife Users Meeting, Carlsbad, CA, 1/1/2005
• Radiosensitization of human cancers by inhibiting MDM2 expression: In vitro and in vivo models and mechanisms.
  Zhang Z, Wang H, Prasad G, Mao L, Oliver P, Bonner J, Agrawal S, Zhang R, American Association for Cancer Research Annual Meeting, Washington, DC, 7/1/2003
• Antisense oligonucleotides targeted to MDM2 oncogene as a novel approach to the treatment of glioblastoma multiforme.
  Prasad G, Wang H, Nan L, Agrawal S, Zhang R, Medical Scientist Training Program 2nd Annual Retreat, Birmingham, AL, 7/1/2001
• Antisense oligonucleotides targeted to MDM2 oncogene as a novel approach to the treatment of glioblastoma multiforme.
  Prasad G, Wang H, Nan L, Zhang Z, Agrawal S, Zhang R, National Student Research Forum, Galveston, TX, 4/1/2001
• Improving chemotherapeutic effectiveness of irinotecan by antisense oligonucleotides.
  Wang H, Wang S, Liang P, Prasad G, Nan L, Agrawal S, Zhang R, American Association for Cancer Research Annual Meeting, New Orleans, LA, 3/1/2001
• Inhibiting MDM2 oncogene expression as a novel approach to the treatment of glioblastoma multiforme.
  Prasad G, Wang H, Nan L, Agrawal S, Zhang R, American Association for Cancer Research Annual Meeting, New Orleans, LA, 3/1/2001
• Inhibiting MDM2 oncogene expression as a novel approach to the treatment of glioblastoma multiforme: an in vitro study.
  Prasad G, University of Alabama School of Medicine – Medical School Research Competition, Birmingham, AL, 11/1/2000
• Pre-clinical pharmacology of desoxyepothilone B, a novel antitumor agent: bioanalytical methods and biostability.
  Wang Z, Liang P, Wang S, Wang H, Prasad G, Nan L, Hill D, Zhang R, University of Alabama at Birmingham Comprehensive Cancer Center Annual Research Retreat, Birmingham, AL, 10/1/2000
• Improving chemotherapeutic effectiveness of irinotecan by antisense oligonucleotides.
  Wang H, Wang S, Liang P, Prasad G, Nan L, Agrawal S, Zhang R, University of Alabama at Birmingham Comprehensive Cancer Center Annual Research Retreat, Birmingham, AL, 10/1/2000
• Inhibiting MDM2 oncogene expression as a novel approach to the treatment of glioblastoma multiforme.
  Prasad G, Wang H, Nan L, Agrawal S, Zhang R, University of Alabama at Birmingham Comprehensive Cancer Center Annual Research Retreat, Birmingham, AL, 10/1/2000
• Paclitaxel-resistant xenografts in nude mice grown directly from human primary tumor biopsies.
  Lee F, Rex S, Wen M, VanDeren C, Prasad G, Arico M, Burke C, Clark J, Fager K, Taglietta D, Fairchild C, Rolf R, Johnson S, Hamilton T, Rose W, American Association for Cancer Research Annual Meeting, San Francisco, CA, 3/1/1998
• Join now to see all

Other

• Inhibition of MDM2 oncogene expression as a novel approach to the treatment of glioblastoma multiforme. Doctoral dissertation 
  Prasad G., University of Alabama, Birmingham
  1/1/2004